Categories: Wire Stories

Cell and Gene Therapy Industry Comes Together for Matica Bio�s New Global Event

COLLEGE STATION, Texas–(BUSINESS WIRE)–Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, hosted an inaugural event this week, Global Cell & Gene Day, with CHA Medical & Bio Group, providing a specialized venue for learning, innovation and networking for the advancing cell and gene therapy market.

Matica Bio has extensive experience in the clinical and commercial production of cell and gene therapies and recently opened its new 25,000-square-foot GMP facility in Texas dedicated to the production of viral vectors and cell-based products used in cell and gene therapies, vaccines, oncolytic therapies and other genetic medicines.

�Matica Bio understands the important role ongoing collaborations have in order to keep pace with this industry’s accelerated clinical development time frames, production complexities and increased demand,” said Matica Bio CEO Yun Jeong Song, M.D. “These include building opportunities for key industry interactions and discussions through events such as Global Cell & Gene Therapy Day, as well as establishing partnerships like ones we have in place with Sartorius and Texas A&M University’s Center for Innovation in Advanced Development and Manufacturing. It is essential that we are all working together as an industry for the future expansion of research, expertise, and successful product development.”

Over 400 attended Global Cell & Gene Day in Pangyo, South Korea. Speakers and topics in the program included a market overview from McKinsey & Co., a discussion on venture capital investment trends from Bain Capital and a summary of clinical trials and regulations from Parexel. Together with these industry experts, Matica Bio shared updates on CMC drug development. Presentations from this event can be made available by request.

Additional events from Matica Bio will be shared at: https://www.maticabio.com/news-upcoming-event.

About Matica Biotechnology, Inc.

Matica Biotechnology is a CDMO specialized for fully integrated cell and gene therapy manufacturing. The industry-leading experts at our state-of-the-art facility in College Station, Texas, deliver breakthrough therapies rapidly and safely through innovative manufacturing solutions. Advance your therapy from idea to patient with the experts at Matica Biotechnology. Visit www.maticabio.com.

Contacts

Lindsey Langemeier

SCORR Marketing

402-405-4269

lindsey@scorrmarketing.com

Alex

Recent Posts

Results of the IX Digital Asset Industry Classification System (“DAICS®”) 2H 2025 Review

HONG KONG SAR - Media OutReach Newswire - 18 December 2025 - IX Asia Indexes…

2 hours ago

Hong Kong Chinese Women’s Club College Wins Gold Award at the 2025 Hang Lung Mathematics Awards

Hang Lung’s Vision for Academic Excellence Drives Hong Kong’s Global CompetitivenessHONG KONG SAR & SHANGHAI,…

12 hours ago

Lever Style Announces Seventh Acquisition Since IPO, Continuing Group Expansion in the Global Apparel Supply Chain Sector

Active Apparel Group Strengthens Lever Style’s Activewear CapabilitiesHONG KONG SAR - Media OutReach Newswire -…

15 hours ago

VinSpeed and Siemens Mobility sign a comprehensive strategic cooperation agreement on high-speed rail

HANOI, VIETNAM - Media OutReach Newswire - 17 December 2025 - VinSpeed High-Speed Railway Investment…

16 hours ago

HKDPB announces key findings of “Hongkongers’ Sense of Security in Savings” Survey for eighth consecutive year

Hongkongers’ average monthly savings rise to a record HK$10,100, while parents with a habit of…

16 hours ago

UABBHK 2025 Officially Opens to Public at Oil Street Art Space and East Kowloon Cultural Centre

HONG KONG SAR - Media OutReach Newswire - 17 December 2025 - The 2025 Hong…

18 hours ago